Why Does Motilal Oswal Expect More Upside in SRF?
About the Brokerage View
Motilal Oswal has reaffirmed its Buy recommendation on SRF with a target price of ₹3,350. The brokerage believes the company's next growth cycle will be driven by record performance in its fluorochemicals business, significant investments in next-generation refrigerants and an expected recovery in specialty chemicals.
Despite temporary weakness in agrochemical-linked demand affecting the specialty chemicals segment, Motilal Oswal expects earnings momentum to strengthen from FY27 as demand gradually improves.
SRF continues to strengthen its position across high-value specialty chemicals and fluorochemicals. The company's investment strategy reflects confidence in long-term demand for environmentally friendly refrigerants and advanced chemical products.
Key Highlights
🔹 Motilal Oswal maintains a Buy rating.
🔹 Target Price: ₹3,350.
🔹 Fluorochemicals revenue grew nearly 60% during FY26.
🔹 ₹23 billion capex planned for next-generation HFO refrigerants.
🔹 Specialty Chemicals recovery expected from FY27.
🔹 EBITDA margin improved to 22.8%.
🔹 Profit after tax increased 49% year-on-year to ₹20.4 billion.
🔹 Brokerage expects approximately 22% PAT CAGR through FY28.
🔹 FY28 EPS estimated at around ₹101.
Investors seeking broader market opportunities may also monitor Nifty Tip insights for overall market direction.
Motilal Oswal Investment Snapshot
| Parameter | Brokerage View |
|---|---|
| Recommendation | Buy |
| Target Price | ₹3,350 |
| Fluorochemicals Growth | 60% Revenue Growth |
| HFO Capex | ₹23 Billion |
| EBITDA Margin | 22.8% |
| Expected PAT CAGR | 22% Through FY28 |
According to Motilal Oswal, SRF's strong balance between capacity expansion, profitability improvement and specialty product development supports its long-term investment case.
Strengths & Weaknesses
|
Strengths
🔹 Strong fluorochemicals growth. 🔹 Improving operating margins. 🔹 Large HFO investment pipeline. 🔹 Healthy earnings visibility. |
Weaknesses
🔹 Specialty chemicals demand remains soft. 🔹 Agrochemical slowdown. 🔹 Capital-intensive expansion. 🔹 Commodity price sensitivity. |
The company's diversified business mix continues to reduce dependence on any single segment while supporting long-term earnings resilience.
Opportunities & Threats
|
Opportunities
🔹 Growing HFO refrigerant demand. 🔹 Specialty chemicals recovery. 🔹 Capacity expansion benefits. 🔹 Export market opportunities. |
Threats
🔹 Global demand slowdown. 🔹 Raw material volatility. 🔹 Project execution delays. 🔹 Competitive pricing pressure. |
Execution of the HFO expansion project and recovery in specialty chemicals will remain key variables influencing SRF's earnings trajectory over the next few years.
Valuation & Investment View
Motilal Oswal believes SRF offers an attractive risk-reward profile, trading at around 27 times estimated FY28 earnings despite expectations of approximately 22% profit CAGR through FY28. Continued investment in advanced fluorochemicals and improving specialty chemicals demand could support long-term value creation.
Investors may also follow BankNifty Tip updates for broader market insights.
Investor Takeaway
Derivative Pro & Nifty Expert Gulshan Khera, CFP®, observes that SRF's combination of capacity expansion, improving profitability and long-term fluorochemicals demand strengthens its investment case. Investors should monitor execution of new projects and the expected recovery in specialty chemicals while evaluating the company's long-term growth potential. Explore more market insights at Indian-Share-Tips.com.
Related Queries on SRF and Specialty Chemicals
🔹 Why is Motilal Oswal bullish on SRF?
🔹 What is driving SRF's fluorochemicals growth?
🔹 What are HFO refrigerants?
🔹 Why is specialty chemicals recovery expected from FY27?
🔹 How does SRF's valuation compare with future earnings growth?
SEBI Disclaimer: This article is for educational and informational purposes only and should not be construed as investment advice. Investors should consult their financial advisor before making investment decisions.
